mometasone Side Effects
Also known as: Asmanex
Analysis of 17,186 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
17,186
Death-Related
814
4.7% of reports
Hospitalizations
5,350
31.1% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 814 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 287 |
| PNEUMONIA | 83 |
| DYSPNOEA | 80 |
| OFF LABEL USE | 63 |
| HYPERSENSITIVITY | 58 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 54 |
| CARDIAC DISORDER | 53 |
| FATIGUE | 52 |
| PLEURAL EFFUSION | 51 |
| WEIGHT DECREASED | 50 |
| ASTHENIA | 48 |
| FALL | 45 |
| RESPIRATORY FAILURE | 41 |
| DIARRHOEA | 40 |
| ANAEMIA | 38 |
| OEDEMA PERIPHERAL | 36 |
| SEPSIS | 36 |
| DRUG INEFFECTIVE | 35 |
| COUGH | 34 |
| ERYTHEMA | 34 |
Reactions in Hospitalization Reports
Top reactions in 5,350 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| DYSPNOEA | 921 |
| ASTHMA | 767 |
| PNEUMONIA | 581 |
| GASTROOESOPHAGEAL REFLUX DISEASE | 557 |
| HEADACHE | 539 |
| WHEEZING | 536 |
| COUGH | 461 |
| FATIGUE | 420 |
| PYREXIA | 409 |
| HYPERTENSION | 399 |
| THERAPEUTIC PRODUCT EFFECT INCOMPLETE | 392 |
| SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION | 369 |
| LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES | 364 |
| DRUG INEFFECTIVE | 354 |
| NAUSEA | 327 |
| CARDIAC DISORDER | 311 |
| PAIN | 308 |
| DIARRHOEA | 302 |
| ASTHENIA | 297 |
| OFF LABEL USE | 297 |
Nearby — Related Medications
What the FAERS Data Reveals About mometasone Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 17,186 voluntary reports linked to mometasone and its brand equivalents (Asmanex), spanning 2004 through 2025. Of those, 814 (4.7%) listed death as an outcome and 5,350 (31.1%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 62% were female and 38% male; age distribution skews toward 45-64, with 4,126 reports in that bracket. The single most reported reaction is dyspnoea with 1,730 submissions, followed by asthma and drug ineffective.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.